Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Q1 FY2027 Earnings Presentation
23 slides from Prestige Consumer Healthcare's earnings presentation, Aug 6, 2026
Slide 1: First Quarter FY 2027 Results
First Quarter FY 2027 Results August 6th, 2026
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted E
Slide 3: I. Performance Highlights
I. Performance Highlights FIRST QUARTER FY 27 RESULTS
Slide 4: First Quarter Performance Exceeded Expectations
First Quarter Performance Exceeded Expectations ◼ Revenue of $265.7 million, up 6.5% versus prior year — Organic revenue(1) growth of 3.2% Q1 Sales ◼ Strong GI and Dermatological category growth Highlights ◼ Eye & Ear Care up; strength in TheraTears® & Debrox® offset Clear Eyes® variability ◼ Includ
Slide 5: Eye Care Supply Remains Dynamic
Eye Care Supply Remains Dynamic Supply Quality Capacity Ramp Category Leadership Continued capex Expanding in-house Production targets designed investment capacity underpins a to support FY 27 sales and strengthening supply multi-year plan to restore improve supply consistency quality and resilience
Slide 6: II. M&A Update
II. M&A Update FIRST QUARTER FY 27 RESULTS
Slide 7: Deals Successfully Closed; Integrations on Track
Deals Successfully Closed; Integrations on Track Breathe Right® & Other OTC Brands LaCorium Health Other Loyalty Brands Closed: June Closed: July ✓ ~$200 million in expected annual revenue ✓ ~$40 million in expected annual revenue ✓ Supports Prestige’s long-term organic growth targets ✓ Historically
Slide 8: Acquisitions Diversify & Enhance Our Iconic Brand Portfolio
Acquisitions Diversify & Enhance Our Iconic Brand Portfolio FY 26 Total Sales by Category Post-Acquisitions Pro Forma Category Sales Mix* Oral Care Other Oral Cough Pain Care & Cold Relief GI GI Cough, Analgesics Cold & Allergy Eye & Ear Care Women’s Skin Health Care Women’s Wellness, Skin Health Sl
Slide 9: An Iconic, Leading Brand Positioned for Growth
An Iconic, Leading Brand Positioned for Growth Brand-Building Innovation International ▪ Iconic brand heritage ▪ Utilize consumer insights to identify ▪ Leverage local distribution partners to innovation that solves needs drive growth in 20+ markets ▪ New, engaging social-oriented ▪ Own nighttime br
Slide 10: III. Financial Overview
III. Financial Overview FIRST QUARTER FY 27 RESULTS
Slide 11: Q1 FY 27 Performance Highlights
Q1 FY 27 Performance Highlights 6.5% Revenue of $265.7 million, up 3.2% vs. prior year on an organic basis(1) $265.7 $249.5 5.5% $84.1 Adjusted EBITDA(2) of $84.1 million, $79.6 3.2% up 5.5% vs. prior year $0.98 $0.95 Adjusted Diluted EPS(2) of $0.98 Revenue Adj. EBITDA (2) Adj. Diluted EPS (2) up v
Slide 12: Q1 FY 27 Consolidated Financial Summary
Q1 FY 27 Consolidated Financial Summary 3 Months Ended* Comments ◼ Organic Revenue (1) up 3.2% vs. prior year Q1 FY 27 Q1 FY 26 % Chg Total Revenue $ 265.7 $ 249.5 6.5% – Strong revenue growth in Gastrointestinal, Dermatologicals categories Adjusted Gross Margin 146.2 140.3 4.2% % Margin 55.0% 56.2%
Slide 13: Free Cash Flow Enabled Capital Deployment
Free Cash Flow Enabled Capital Deployment Free Cash Flow Comments Q1 FY 27 Q1 FY 26 ◼ Solid Q1 Adjusted Free Cash Flow(2) of $83.7 million – Change primarily from timing of working capital 7.1% ◼ Net Debt at June 30th of ~$2.0 billion(2), following purchase $83.7 of Breathe Right® and certain other
Slide 14: IV. FY 27 Outlook
IV. FY 27 Outlook FIRST QUARTER FY 27 RESULTS
Slide 15: Updated FY 27 Outlook
Updated FY 27 Outlook Previously-Issued Outlook Current Outlook ◼ Revenues of $1,290 to $1,315 million ◼ Revenues of $1,100 to $1,121 million Top Line — Organic growth of approximately 1% to 3% — Organic growth of approximately 1% to 3% Trends ◼ Projecting improved shipment trends in eye care ◼ ~$19
Slide 16: Appendix
Appendix FIRST QUARTER FY 27 RESULTS
Slide 17: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated August 6, 2026 in the “About Non-GAAP Financial Measures” section. (2) Adjusted Gross Profit,
Slide 18: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Change Three Months Ended June 30, 2026 2025 (In Thousands) GAAP Total Revenues $ 265,710 $ 249,530 Revenue Change 6.5% Adjustments: Revenues associated with acquisition(a) (5,945) Impact of foreign currency exchange rates 2,086 Total adjustments $ (5,945) $
Slide 19: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted G&A Expense Three Months Ended June 30, 2026 2025 (In thousands) GAAP General and Administrative Expense $ 43,303 $ 28,456 GAAP General and Administrative Expense as a Percentage of GAAP Total 16.3% 11.4% Revenue Adjustments: Costs associated with acquis
Slide 20: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted EBITDA and EBITDA Margin Adjusted Free Cash Flow Three Months Ended June 30, Three Months Ended June 30, 2026 2025 2026 2025 (In Thousands) (In Thousands) GAAP Net Income $ 29,177 $ 47,466 GAAP Net Income $ 29,177 $ 47,466 Interest expense, net 13,945 10
Slide 21: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Net Income & Adjusted Diluted EPS Three Months Ended June 30, Nine Months Ended December 31, 2026 2025 Adjusted Adjusted Net Income EPS Net Income EPS (In Thousands, except per share data) GAAP Net Income and Diluted EPS $ 29,177 $ 0.61 $ 47,466 $ 0.95 A
Slide 22: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Projected Adjusted Earnings Per Share* Low High Projected FY'27 GAAP Diluted EPS $ 4.18 $ 4.28 Adjustments: Costs associated with Pillar5 manufacturing optimization and integration 0.13 0.13 Costs associated with acquisitions of the Breathe Right portfolio & LaCo
Slide 23: Latest FY 27 Financial Outlook
Latest FY 27 Financial Outlook Metric Guidance ◼ $1.290 to $1.315 billion Revenue ◼ Organic growth of 1% to 3%(1) Gross Margin ◼ Just over 57% Marketing ◼ ~14.5% of net revenue General & Administrative ◼ ~10.0% of net revenue Interest Expense ◼ ~$100 million in interest expense Tax Rate ◼ ~24% effec
Prestige Consumer Healthcare — Q1 FY2027 Earnings Presentation on 6ix